Investigational Treatment for Hypereosinophilic Syndrome Granted Orphan Drug Status
Orphan Drug designation allows companies a 7-year marketing exclusivity period, should the treatment be approved. Click to View Article
Yearly Archives: 2019
AdColony cofounder joins online fundraising platform Omaze as president
How would you like to buy lunch with Will Kassoy, the new president of Omaze? I’m just kidding, but Kassoy has joined a company that makes such things possible. Click to View Article
YieldStreet Acquires Athena Art Finance for $170M
YieldStreet, the alternative investment platform for retail investors, has agreed to acquire Athena Art Finance from the Carlyle Group and its co-investors for $170M. Click to View Article
Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson
Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson Click to View Article
YieldStreet Raises $62M To Bring Alternative Investing To The Masses
YieldStreet, the fintech startup bringing alternative investments to the masses, has raised $62 million in financing, led by Edison Partners, the growth equity investment firm. Click to View Article
YieldStreet’s Alternative Investment Marketplace Booms In Times Of Volatility
When YieldStreet launched a $6.45 million offering on its marketplace, it expected a lot of investors to get in on the deal. After all, they had about seventy-two hours to digest all the important aspects of the company and the … Continued
Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases
Dr. Patricia Fulkerson, an authority in eosinophil biology, will analyze effects of dexpramipexole in stem cell culture system Click to View Article